TIMP2 and neoplasm: This new concept is supported by (1) the ability of ADAMTS-1 to bind VEGF and functionally inactivate VEGFR2 (Iruela-Arispe et al, 2003), (2) the existence of a correlation between VEGF and some MMP expression in tumours, (3) the upregulation of VEGF-A expression by the active form of membrane type-1 MMP (MT1-MMP, MMP14) (Munaut et al, 2003), (4) the reduction of VEGF expression in tumour cells by physiological inhibitor (TIMP-2) (Hajitou et al, 2001) or synthetic inhibitor (Sounni et al, 2004) of MMPs.